- Home
- NGS vs EYPT Comparison
NGS vs EYPT Comparison
Compare NGS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGS | EYPT |
|---|---|---|
| Founded | 1998 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Laboratory Analytical Instruments |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.6M | 419.9M |
| IPO Year | 2006 | 2005 |
Fundamental Metrics
Financial Performance| Metric | NGS | EYPT |
|---|---|---|
| Price | $35.61 | $4.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $40.67 | $31.80 |
| AVG Volume (30 Days) | 95.8K | ★ 6.3M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | ★ 14.60 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $172,315,000.00 | $7,539,000.00 |
| Revenue This Year | $15.05 | N/A |
| Revenue Next Year | $9.52 | $3,115.57 |
| P/E Ratio | $43.25 | ★ N/A |
| Revenue Growth | ★ 9.94 | N/A |
| 52 Week Low | $25.53 | $3.95 |
| 52 Week High | $44.61 | $19.11 |
Technical Indicators
Market Signals| Indicator | NGS | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 29.97 |
| Support Level | $34.45 | $3.95 |
| Resistance Level | $39.56 | $15.17 |
| Average True Range (ATR) | 1.16 | 0.51 |
| MACD | 0.12 | -0.08 |
| Stochastic Oscillator | 40.13 | 26.30 |
Price Performance
Historical ComparisonAbout NGS Natural Gas Services Group Inc.
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. It operates in one reporting segment. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.